Your browser is no longer supported. Please, upgrade your browser.
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-1.09 Insider Own1.40% Shs Outstand89.25M Perf Week11.04%
Market Cap1.62B Forward P/E- EPS next Y-0.08 Insider Trans-64.00% Shs Float68.30M Perf Month-16.20%
Income-95.00M PEG- EPS next Q-0.17 Inst Own48.70% Short Float8.15% Perf Quarter-4.74%
Sales125.20M P/S12.90 EPS this Y58.00% Inst Trans-0.81% Short Ratio6.04 Perf Half Y69.16%
Book/sh1.33 P/B13.61 EPS next Y89.60% ROA-34.70% Target Price25.40 Perf Year161.18%
Cash/sh2.07 P/C8.76 EPS next 5Y60.00% ROE-69.50% 52W Range5.95 - 22.30 Perf YTD130.57%
Dividend- P/FCF- EPS past 5Y- ROI-52.70% 52W High-17.38% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin62.50% 52W Low209.66% ATR0.96
Employees460 Current Ratio6.70 Sales Q/Q114.50% Oper. Margin-59.90% RSI (14)45.83 Volatility5.43% 5.15%
OptionableYes Debt/Eq0.82 EPS Q/Q49.60% Profit Margin-75.90% Rel Volume0.37 Prev Close18.10
ShortableYes LT Debt/Eq0.82 EarningsOct 26 BMO Payout- Avg Volume921.36K Price18.42
Recom1.80 SMA20-2.87% SMA50-6.25% SMA20033.97% Volume189,035 Change1.80%
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-27-15Initiated Wedbush Outperform
Oct-27-15Initiated JP Morgan Overweight
Oct-27-15Initiated JMP Securities Mkt Outperform $43
Oct-22-17 12:15PM  3 Healthcare Stocks for Your Radar Motley Fool
Oct-17-17 08:45AM  NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-16-17 04:30PM  Why Rite Aid, Hudbay Minerals, and NovoCure Jumped Today Motley Fool +8.28%
07:30AM  Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer Business Wire
Oct-03-17 11:53AM  Novocure Ltd. Value Analysis (NASDAQ:NVCR) : October 3, 2017 Capital Cube
Oct-02-17 08:22AM  Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017 Capital Cube
07:00AM  Novocure to Report Third Quarter 2017 Financial Results Business Wire
Sep-25-17 09:40AM  Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers TheStreet.com
Sep-24-17 06:15PM  Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients Business Wire
Sep-22-17 07:00AM  Novocure Announces Data Presentations at the American Society for Radiation Oncologys 2017 Annual Meeting Business Wire
Sep-19-17 07:15AM  3 Innovation-Forward Healthcare Stocks to Buy Now Motley Fool
Sep-14-17 02:29PM  Dolby Laboratories is a stock to watch after Apples new iPhone launch MarketWatch
Sep-06-17 07:00AM  Novocure Announces Data Presentations at the ESMO 2017 Congress Business Wire
Sep-05-17 07:41AM  German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Aug-28-17 08:23AM  If You Love Intuitive Surgical, You Should Check Out This Small-Cap Growth Stock Motley Fool
Aug-24-17 07:00AM  Novocure to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-22-17 02:21PM  Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-16-17 06:00AM  3 Stocks That Could Soar More Than Priceline Motley Fool
Aug-15-17 09:01PM  3 Game-Changing Small-Cap Healthcare Stocks Motley Fool
Aug-11-17 06:10PM  ETFs with exposure to Novocure Ltd. : August 11, 2017 Capital Cube
Aug-08-17 09:25AM  Novocure Announces National Reimbursement for Optune® in Austria Business Wire +5.23%
Aug-02-17 05:31PM  3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment Motley Fool
07:00AM  Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-17 10:07AM  3 Hot Healthcare Stocks Under $30 Motley Fool
Jul-28-17 12:38PM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
12:28AM  NovoCure reports 2Q loss Associated Press
Jul-27-17 06:15AM  Investor Network: Novocure Ltd. to Host Earnings Call ACCESSWIRE +5.97%
06:00AM  Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
Jul-24-17 07:22AM  Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma Business Wire
Jul-20-17 06:21PM  Many treatment options, most experimental, available to John McCain Reuters
Jul-18-17 08:16AM  These 2 Companies Have No Competition Motley Fool
Jul-13-17 06:07AM  The Fastest Growing Cancer Company You've Never Heard Of Motley Fool
Jul-12-17 08:47AM  NovoCure (NVCR) Jumps: Stock Rises 10.5% Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. Accesswire
07:30AM  Novocures Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S. Business Wire
Jul-11-17 06:03PM  Why Novocure Shares Jumped 10.5% Today Motley Fool +10.50%
07:30AM  Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society Business Wire
06:20AM  Warren Buffett Has the Edge Over Paul Singer, Oncor CEO Tells TheStreet's Jim Cramer on 'Mad Money' TheStreet.com
Jul-10-17 07:45PM  Cramer Remix: Not just fun and games, this stock is the r... CNBC Videos
06:59PM  Cramer Remix: Not just fun and games, this stock is the real deal CNBC
Jun-30-17 08:38AM  Is NovoCure (NVCR) a Great Growth Stock? Zacks
07:00AM  Novocure to Report Second Quarter 2017 Financial Results Business Wire
Jun-28-17 08:47AM  Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer Business Wire
Jun-13-17 04:30PM  Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference Business Wire
Jun-08-17 06:30AM  First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma Business Wire
Jun-05-17 07:00AM  Health Care Service Corporation Issues Positive Coverage Decision for Optune Business Wire
Jun-02-17 08:13AM  3 Stocks That Could Double Your Money Motley Fool
07:30AM  Novocure to Present at the JMP Securities 2017 Life Sciences Conference Business Wire
May-24-17 11:19AM  Shark Bites: Focus on the 'Little Picture' TheStreet.com +12.50%
May-15-17 07:25AM  Novocure Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma Business Wire
May-11-17 08:12AM  Martin J. Madden Joins Novocure Board of Directors Business Wire
May-08-17 07:00AM  Combination of Optune with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients Business Wire +5.93%
May-04-17 07:00AM  Novocure Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas Business Wire
May-01-17 07:50PM  Edited Transcript of NVCR earnings conference call or presentation 27-Apr-17 12:00pm GMT Thomson Reuters StreetEvents
04:12PM  ETFs with exposure to Novocure Ltd. : May 1, 2017 Capital Cube
07:30AM  Novocure to Present at Three Upcoming Investor Conferences in May Business Wire
07:25AM  Novocure Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting Business Wire
Apr-28-17 11:10AM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
Apr-27-17 06:35AM  NovoCure reports 1Q loss Associated Press
06:00AM  Novocure Reports First Quarter 2017 Financial Results and Provides Company Update Business Wire
Apr-19-17 07:00AM  Novocure Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston Business Wire
Apr-17-17 07:31AM  Novocure says drug shows better survival rates for cancer patients in late-stage trial MarketWatch
07:00AM  CNS Oncology Publishes Data Suggesting Survival Benefit of Optune in Combination with Second Line Chemotherapies after Glioblastoma Recurrence Business Wire
Apr-12-17 02:04PM  5 Top Stocks to Buy in April Motley Fool
Apr-08-17 09:51AM  What Investors Missed in the Market This Week Motley Fool
Apr-07-17 09:25AM  Endo international, AngioDynamics Lead Biotech Movers TheStreet.com
Apr-05-17 05:11PM  ETFs with exposure to Novocure Ltd. : April 5, 2017 Capital Cube
Apr-04-17 09:15AM  Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News Accesswire -9.46%
Apr-03-17 05:55PM  After-hours buzz: PRTK, MRCY, NVCR CNBC +37.04%
04:34PM  Why NovoCure, Lumber Liquidators, and SodaStream International Jumped Today Motley Fool
01:06PM  Here's Why NovoCure Ltd. Is Skyrocketing Today Motley Fool
12:22PM  Why Bulls Are Piling Into Novocure Ltd (NVCR) Today Insider Monkey
11:40AM  Novocure Glioblastoma Drug Offers Survival Benefits Investopedia
11:29AM  Novocure Ltd. stock surges nearly 50% after positive late-stage trial results in brain cancer MarketWatch
11:17AM  Novocure shares skyrocket 50% after positive trial results CNBC
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma TheStreet.com
09:05AM  Why NovoCure Shares Are Skyrocketing
07:30AM  US STOCKS-Futures flat as earnings, Trump-Xi talks loom
Apr-02-17 11:00AM  Combination of Optune with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients Business Wire
Mar-31-17 04:30PM  Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer Business Wire
04:30PM  Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer Business Wire
04:07PM  NOVOCURE LTD Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
08:05AM  Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma Business Wire
Mar-28-17 07:00AM  Novocure to Report First Quarter 2017 Financial Results Business Wire +5.26%
06:50AM  Novocure to Present at the 16th Annual Needham & Company Healthcare Conference Business Wire
Mar-27-17 04:06PM  NOVOCURE LTD Files SEC form 8-K, Change in Directors or Principal Officers +7.80%
08:06AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : March 27, 2017
Mar-20-17 07:00AM  Novocure Receives MHLW Approval for Second Generation Optune® in Japan Business Wire
Mar-01-17 04:49PM  Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017 Business Wire +5.26%
Feb-28-17 01:04PM  NOVOCURE LTD Financials
Feb-27-17 11:56AM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017 +8.70%
Feb-23-17 01:40PM  Edited Transcript of NVCR earnings conference call or presentation 23-Feb-17 1:00pm GMT
09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results
08:15AM  NOVOCURE LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q4 2016 Novocure Ltd Earnings Release - Before Market Open
06:30AM  NovoCure reports 4Q loss
06:05AM  Novocure Announces Departure of Chief Commercial Officer Business Wire
06:00AM  Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update Business Wire
Feb-17-17 10:35AM  If You're in Your 30s, Consider Buying These Stocks at Motley Fool
07:53AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : February 17, 2017
Markets a wearable electric field device for treating glioblastoma brain cancer.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Danziger AsafChief Executive OfficerSep 25Sale22.0590019,845774,190Sep 27 04:18 PM
Danziger AsafChief Executive OfficerSep 14Sale22.001,77238,984775,090Sep 15 04:05 PM
Danziger AsafChief Executive OfficerSep 13Sale22.0135,500781,518776,862Sep 15 04:05 PM
Danziger AsafChief Executive OfficerJul 14Option Exercise0.38354,780134,816812,362Jul 18 04:48 PM
Danziger AsafChief Executive OfficerJul 11Sale19.957,383147,325457,582Jul 13 04:14 PM
Danziger AsafChief Executive OfficerJul 10Sale18.08203,9003,685,900464,965Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 07Sale18.0370,4591,270,658668,865Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 06Sale18.095,05091,344739,324Jul 07 04:33 PM
Danziger AsafChief Executive OfficerJul 05Sale18.14155,0882,813,917744,374Jul 07 04:33 PM
Pomona Capital VII, L.P.10% OwnerJun 26Sale17.4699,3411,734,1862,741,925Jun 27 04:11 PM
Pomona Capital VII, L.P.10% OwnerJun 23Sale17.34973,19116,872,8942,772,870Jun 27 04:11 PM
Kirson Eilon D.Chief Science OfficerJun 21Sale16.7866,3611,113,206222,722Jun 22 04:29 PM
Kirson Eilon D.Chief Science OfficerJun 19Sale15.0615,000225,885289,083Jun 21 04:19 PM
Danziger AsafChief Executive OfficerJun 19Sale15.51124,7201,934,906896,917Jun 21 04:17 PM
Danziger AsafChief Executive OfficerJun 16Sale15.029,212138,3461,021,637Jun 19 04:31 PM
Danziger AsafChief Executive OfficerJun 15Sale15.1933,245504,8921,030,849Jun 19 04:31 PM
DOYLE WILLIAM FDirectorJun 14Option Exercise3.596,49823,32891,197Jun 15 04:23 PM
Danziger AsafChief Executive OfficerJun 14Sale15.015,40281,0681,064,094Jun 15 04:17 PM
Kirson Eilon D.Chief Science OfficerJun 13Sale15.019,044135,769304,083Jun 15 04:28 PM
Danziger AsafChief Executive OfficerJun 13Sale15.2388,7001,351,0781,069,496Jun 15 04:17 PM
Kirson Eilon D.Chief Science OfficerJun 12Sale15.085,95689,828313,127Jun 13 06:19 PM
Danziger AsafChief Executive OfficerJun 12Sale15.095,10076,9341,158,196Jun 13 06:35 PM
Danziger AsafChief Executive OfficerJun 09Sale15.13175,5012,654,9791,163,296Jun 13 06:35 PM
Kirson Eilon D.Chief Science OfficerJun 09Sale15.0215,000225,225319,083Jun 13 06:19 PM
Palti YoramChief Technology OfficerJun 05Sale13.823,82552,8420Jun 06 05:17 PM
Palti YoramChief Technology OfficerJun 02Sale13.494,00053,9563,825Jun 05 04:19 PM
Palti YoramChief Technology OfficerJun 01Sale13.054,00052,1847,825Jun 05 04:19 PM
Palti YoramChief Technology OfficerMay 31Sale12.474,00049,89211,825Jun 01 04:29 PM
Palti YoramChief Technology OfficerMay 30Sale12.504,00050,00415,825Jun 01 04:29 PM
Palti YoramChief Technology OfficerMay 26Sale12.864,00051,44019,825May 30 05:08 PM
Palti YoramChief Technology OfficerMay 25Sale12.894,00051,56423,825May 30 05:08 PM
Palti YoramChief Technology OfficerMay 24Sale13.154,00052,61227,825May 25 04:21 PM
Palti YoramChief Technology OfficerMay 23Sale11.804,00047,20031,825May 24 04:31 PM
Palti YoramChief Technology OfficerMay 22Sale11.674,00046,67635,825May 24 04:31 PM
Palti YoramChief Technology OfficerMay 19Sale11.544,00046,14439,825May 22 04:14 PM
Palti YoramChief Technology OfficerMay 18Sale11.244,00044,95643,825May 22 04:14 PM
Palti YoramChief Technology OfficerMay 17Sale11.474,00045,88447,825May 18 05:52 PM
Palti YoramChief Technology OfficerMay 16Sale11.904,00047,60451,825May 17 04:14 PM
Palti YoramChief Technology OfficerMay 15Sale12.194,00048,75655,825May 17 04:14 PM
Palti YoramChief Technology OfficerMay 10Sale12.254,00048,99267,825May 11 04:04 PM
Palti YoramChief Technology OfficerMay 09Sale12.334,00049,30871,825May 11 04:04 PM
Palti YoramChief Technology OfficerMay 08Sale12.094,00048,37675,825May 09 04:03 PM
Palti YoramChief Technology OfficerMay 05Sale11.554,00046,20079,825May 09 04:03 PM
Palti YoramChief Technology OfficerMay 04Sale11.294,00045,14483,825May 05 04:05 PM
Palti YoramChief Technology OfficerMay 03Sale11.554,00046,21687,825May 05 04:05 PM
Palti YoramChief Technology OfficerMay 02Sale11.844,00047,34491,825May 03 04:05 PM
Palti YoramChief Technology OfficerMay 01Sale11.444,00045,77695,825May 03 04:05 PM
Palti YoramChief Technology OfficerApr 28Sale11.294,00045,16099,825May 01 04:07 PM
Palti YoramChief Technology OfficerApr 27Sale11.214,00044,820103,825May 01 04:07 PM
Palti YoramChief Technology OfficerApr 26Sale10.784,00043,100107,825Apr 27 04:05 PM
Palti YoramChief Technology OfficerApr 25Sale10.794,00043,164111,825Apr 27 04:05 PM
Palti YoramChief Technology OfficerApr 24Sale11.064,00044,244115,825Apr 25 04:05 PM
Palti YoramChief Technology OfficerApr 21Sale11.454,00045,804119,825Apr 25 04:05 PM
Palti YoramChief Technology OfficerApr 20Sale11.464,00045,820123,825Apr 21 04:05 PM
Palti YoramChief Technology OfficerApr 19Sale11.034,00044,132127,825Apr 21 04:05 PM
Palti YoramChief Technology OfficerApr 18Sale10.644,00042,556131,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 17Sale10.774,00043,076135,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 13Sale10.434,00041,724139,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 12Sale10.724,00042,864143,825Apr 19 04:09 PM
Perlhagen Gert L.DirectorMar 14Buy6.93125,000866,2506,125,000Mar 16 04:06 PM
DOYLE WILLIAM FExecutive ChairmanFeb 28Option Exercise3.591,212,4544,352,71020,024,052Mar 02 07:21 PM
Ambrogi Michael J.Chief Operating OfficerDec 22Sale8.097,50060,695131,584Dec 22 04:59 PM
Ambrogi Michael J.Chief Operating OfficerDec 21Sale8.3320,000166,608139,084Dec 22 04:59 PM
Ambrogi Michael J.Chief Operating OfficerDec 20Sale8.6220,000172,476159,084Dec 21 04:50 PM
Ambrogi Michael J.Chief Operating OfficerDec 19Sale8.7620,000175,178179,084Dec 21 04:50 PM
Ambrogi Michael J.Chief Operating OfficerDec 16Sale8.7120,000174,270199,084Dec 19 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 15Sale9.1420,000182,858219,084Dec 19 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 14Sale8.9620,000179,294239,084Dec 15 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 13Sale8.9820,000179,688259,084Dec 15 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 12Sale9.0410,00090,442279,084Dec 13 04:06 PM
Ambrogi Michael J.Chief Operating OfficerDec 09Sale8.935,00044,668289,084Dec 13 04:06 PM
Ambrogi Michael J.Chief Operating OfficerDec 08Sale8.375,00041,832294,084Dec 09 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 07Sale8.245,00041,175299,084Dec 09 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 06Sale8.225,00041,110304,084Dec 07 04:05 PM
Kirson Eilon D.Chief Scientific OfficerDec 05Option Exercise0.17156,07326,532334,083Dec 06 04:05 PM
Ambrogi Michael J.Chief Operating OfficerDec 05Sale8.255,00041,245309,084Dec 07 04:05 PM